[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-neoplasm":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,61,84,141,166,193,220,247,271,292,317,338,360,377,398,444,471,517],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100546861","phase-1-a-study-of-ly4170156-in-participants-with-selected-advanced-solid-tumors-100546861",false,"NCT06400472","A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","A First-in-Human, Phase 1a\u002F1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)\n  * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer\n  * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n* Individual with history of carcinomatous meningitis\n* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n* History of pneumonitis\u002Finterstitial lung disease\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","ALL","18 Years",{"count":19,"type":20},495,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.",[26,27,28,29,30,31,32],"Ovarian Neoplasms","Endometrial Neoplasms","Uterine Cervical Neoplasms","Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Neoplasms","Pancreatic Neoplasm","Colorectal Neoplasms",[34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Folate receptor alpha","NSCLC","Ovarian cancer","Cervical cancer","Endometrial cancer","Solid tumor","Lung cancer","Breast cancer","Pancreatic cancer","Colorectal cancer","Anti-drug conjugate","Phase I","Chemotherapy","sofe-m","RECRUITING","2026-06-17",{"date":51,"type":52},"2026-06-18","ACTUAL",{"date":54,"type":52},"2024-05-20",{"date":56,"type":20},"2027-04",{"name":58,"class":59},"Eli Lilly and Company","INDUSTRY",23,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100380898","comparing-the-clinical-impact-of-pancreatic-cyst-surveillance-programs-and-associated-biomarkers-100380898","NCT04239573","Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers","Inclusion Criteria:\n\n* Patient must be ≥ 50 years and ≤ 75 years of age\n* Patient must not have acute pancreatitis or a history of chronic pancreatitis\n* Patient must have received a CT, MRI, or EUS within 6 months prior to enrollment that revealed one or more ≥ 1 cm pancreatic cyst(s).\n* Patients of childbearing potential must not be known to be pregnant\n* Patient must not have a prior diagnosis of pancreatic malignancy of any type\n* Patient must not have a history of pancreatic resection\n* Patients with only pancreatic lesions without malignant risk (pancreatic pseudocyst or classic serous cystic lesion) are not eligible\n* Patient must not have a family history of pancreatic adenocarcinoma in one or more first-degree relatives (biological parents, full siblings or children)\n* Patient must not have pancreatic cyst morphology that would prompt immediate surgical consideration (enhancing mural nodule, solid component in cyst, pancreatic duct ≥ 10mm, cyst causing obstructive jaundice)\n* Patient must not have a comorbid illness that precludes EUS or pancreatic cyst resection\n* Patient must not be in any form of pancreatic cyst surveillance for \\> 1 year, defined as organized, periodic up-to-date imaging directed towards the pancreatic cyst of interest\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must be ≥ 50 years and ≤ 75 years of age\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must not have acute pancreatitis or a history of chronic pancreatitis.\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must have received a CT, MRI, or EUS within 6 months prior to randomization that revealed one or more ≥ 1 cm pancreatic cyst (s).\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patients of childbearing potential must not be known to be pregnant.\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must not have a prior diagnosis of pancreatic malignancy of any type.\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must not have a history of pancreatic resection.\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patients with only pancreatic lesions without malignant risk (pancreatic pseudocyst or classic serous cystic lesion) are not eligible.\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must not have a family history of pancreatic adenocarcinoma in one or more first-degree relatives (biological parents, full siblings or children).\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must not have pancreatic cyst morphology that would prompt immediate surgical consideration (enhancing mural nodule, solid component in cyst, pancreatic duct ≥10mm, cyst causing obstructive jaundice).\n* PRIOR TO ADDENDUM #5 08\u002F13\u002F2024: Patient must not have a comorbid illness that precludes EUS or pancreatic cyst resection.","50 Years","75 Years",{"count":70,"type":20},770,"OBSERVATIONAL","The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as identify biomarkers which may improve risk detection of transformation to pancreatic cancer. The study doctors want to learn which monitoring method and which biomarkers lead to better outcomes for patients.",[31],"2026-06-16",{"date":49,"type":52},{"date":77,"type":52},"2020-06-16",{"date":79,"type":20},"2031-12-31",{"name":81,"class":82},"ECOG-ACRIN Cancer Research Group","NETWORK",424,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":115,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100520064","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mesothelin-targeting-logic-gated-car-t-in-participants-with-solid-tumors-that-express-msln-and-have-lost-hla-a02-expression-100520064","NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion",{"count":93,"type":20},474,[23,95],"PHASE2","The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[98,99,35,100,101,102,103,31,104,105,106,107,108,109,26,110,111,112,113,114],"Solid Tumor, Adult","Colorectal Cancer","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreas Cancer","Colorectal Adenocarcinoma","CRC","Colon Cancer","Rectal Cancer","Cancer","Ovarian Cancer","Mesothelioma","Mesothelioma, Malignant","Ovary Cancer","Lung Cancer","MESOM",[116,117,118,119,120,121,122,123,124,125,126,127,108,128,105,99,113,35,129,114,109,110,130],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Pancreatic","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate","2026-06-10",{"date":133,"type":52},"2026-06-12",{"date":135,"type":52},"2024-04-03",{"date":137,"type":20},"2029-06",{"name":139,"class":59},"A2 Biotherapeutics Inc.",12,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":165},"100637717","endoscopic-ultrasound-guided-pulsed-electric-field-ablation-for-the-treatment-of-pancreatic-neoplasms-100637717","NCT07619417","Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms","Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation of Pancreatic Neoplasms - A Safety and Feasibility Trial","Inclusion Criteria:\n\n* Age \\> 18 years\n* A diagnosis of a pancreatic neoplasm confirmed by EUS-fine needle aspiration (FNA) - (a) pancreatic cystic lesion such as intraductal papillary-mucinous neoplasm (IPMN), (b) World Health Organization (WHO) grade I neuroendocrine tumor\n* Lesion size estimation by computed tomography (CT) or magnetic resonance imaging (MRI)\u002Fmagnetic resonance cholangiopancreatography (MRCP) or EUS: (a) pancreatic cystic lesion such as IPMN - at least 2 cm in diameter. (b) WHO grade I neuroendocrine tumor - at least 1 cm in diameter\n* The patient is not a surgical candidate. Common clinical scenarios include -\n\n  * Cirrhosis of the liver (common clinical scenario)\n  * Advanced (≥ 75 years) age (common clinical scenario)\n  * Morbid obesity\n  * Significant cardiorespiratory comorbidity\n  * Patient's choice (patient elects for non-surgical management)\n  * Other significant comorbid conditions that impose prohibitive surgical risks\n  * The patient prefers non-surgical management after consultation with hepato-pancreato-biliary (HPB) surgery\n* For pancreatic neuroendocrine tumor (PNET) and all pancreatic cystic lesions (PCLs): Estimated life expectancy of at least 1 year\n* Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them\n* Women of childbearing potential must have a negative pregnancy test (serum\u002Furine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy\n* The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-RFA (Ohio State University \\[OSU\\] Institutional Review Board \\[IRB\\] protocol: 2023C0004)\n\nExclusion Criteria:\n\n* Any evidence of severe or uncontrolled systemic diseases, or laboratory findings that, in the investigator's opinion, make it unsafe for the patient to participate in the study study\n* Pregnancy or breast-feeding\n* Clinical frailty scale\n* Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC)",{"count":140,"type":20},[150],"NA","This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.",[31,153],"Pancreatic Neuroendocrine Tumor","NOT_YET_RECRUITING","2026-05-27",{"date":157,"type":52},"2026-06-02",{"date":159,"type":20},"2026-08-01",{"date":161,"type":20},"2027-12-31",{"name":163,"class":164},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":177,"conditions":178,"keywords":183,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100525527","early-phase-1-prospective-screening-for-pancreatic-ductal-adenocarcinoma-in-high-risk-individuals-100525527","NCT06122896","Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","Inclusion Criteria:\n\nParticipants must meet any of the following:\n\n* Individuals with pathogenic\u002Flikely pathogenic germline variants in STK11, and age ≥30 years.\n* Individuals with pathogenic\u002Flikely pathogenic germline variants in CDKN2A, and age ≥40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).\n* Individuals with pathogenic\u002Flikely pathogenic germline variants in one of the other pancreatic cancer susceptibility genes (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53), and age ≥50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) AND\n\n  • Exocrine pancreatic cancer in ≥1 first- or second-degree relative from the same side of (or presumed to be from the same side of) the family as the identified pathogenic\u002Flikely pathogenic germline variant.\n* Individuals with pathogenic\u002Flikely pathogenic variants in PRSS1 AND a clinical phenotype consistent with hereditary pancreatitis, and age ≥40 years (or 20 years after onset of pancreatitis, whichever is earlier).\n* Individuals with familial pancreatic cancer including:\n\n  * Family history of exocrine pancreatic cancer in ≥2 first-degree relatives from the same side of the family, even in the absence of a known pathogenic\u002Flikely pathogenic germline variant, OR\n  * Family history of exocrine pancreatic cancer in 1 affected first-degree relative and 1 second-degree relative, even in the absence of a known pathogenic\u002Flikely pathogenic germline variant, OR\n  * Family history of exocrine pancreatic cancer in ≥3 first- and\u002For second-degree relatives from the same side of the family, even in the absence of a known pathogenic\u002Flikely pathogenic germline variant.\n* Individuals who are undergoing clinically recommended pancreatic cancer surveillance.\n\nExclusion Criteria:\n\n* Individuals with active or prior pancreatic ductal adenocarcinoma diagnosis.\n* Individuals with any active metastatic cancer.\n* Individuals who are unable to give informed consent.\n* Individuals who are under the age of 18 (infants, children, teenagers).\n* Individuals unable to tolerate Magnetic Resonance Imaging\u002FMagnetic Resonance Cholangiopancreatography and Endoscopic Ultrasound.\n* Pregnant women are unlikely to be undergoing screening procedures and will not be considered eligible but can consent to the study at a later date.",true,{"count":174,"type":20},5000,[176],"EARLY_PHASE1","The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.",[179,180,181,182,31],"Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma",[179,180,181,182,31],{"date":185,"type":52},"2026-05-29",{"date":187,"type":52},"2023-11-21",{"date":189,"type":20},"2041-10-31",{"name":191,"class":164},"Dana-Farber Cancer Institute",2,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":219},"100492052","phase-1-testing-the-addition-of-sunitinib-malate-to-lutetium-lu-177-dotatate-lutathera-in-pancreatic-neuroendocrine-tumors-100492052","NCT05687123","Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed metastatic or unresectable well- or moderately-differentiated pancreatic neuroendocrine tumors (PNETs) of all grades (Grade 1, grade 2 and grade 3)\n* Patients with measurable disease per RECIST 1.1 appropriate for lutetium Lu 177 dotatate treatment, as determined by positive screening with SSR PET\u002FCT and appropriate theranostics consultation (nuclear medicine or radiation oncology consultation)\n* Patients may be treatment naïve or have disease progression on or intolerance of up to one line of systemic therapy other than somatostatin analog therapy (somatostatin analog therapy is not considered a line of systemic therapy). Systemic therapy is considered therapy for unresectable or metastatic disease. Any prior adjuvant therapy with curative intent will not be considered a line unless relapse occurs within 6 months. Prior and\u002For concurrent use of somatostatin analogs are allowed\n* Patients who have have received a prior line of therapy must have documented disease progression per RECIST 1.1 within 12 months of initiation of the study protocol\n* Age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of sunitinib malate in combination with lutetium Lu 177 dotatate in patients \\\u003C 18 years of age, children are excluded from this study\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Absolute neutrophil count \\>= 1,000\u002FmcL\n* Platelets \\>= 75,000\u002FmcL\n* Total bilirubin =\\\u003C 1.5 institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3 × institutional ULN\n* Creatinine clearance \\> 50 ml\u002Fmin OR Glomerular filtration rate (GFR) \\>= 60 mL\u002Fmin\u002F1.73 m\\^2\n* Hemoglobin \\> 8.0 g\u002FdL\n* White blood cell count \\> 2000\u002FmL\n* Serum calcium =\\\u003C 12.0 mg\u002FdL\n* International normalized ratio (INR) =\\\u003C 1.5\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have left ventricular ejection fraction of 50% or more. (Patients with no known history and no current symptoms of cardiac disease do not require left ventricular ejection fraction \\[LVEF\\] evaluation at screening)\n* Patients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility. Initiation or adjustment of BP medication is permitted prior to study entry, provided that the average of three BP readings at a visit prior to enrollment is less than 140\u002F90 mmHg\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, as determined by a repeat imaging study at least 4 weeks following the completion of treatment. Patients with treated brain metastases must also be off steroids for at least 1 month and stable\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial after consultation with the study chair\n* The effects of lutetium Lu 177 dotatate and sunitinib malate on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because radionucleotides and anti-angiogenic agents are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. All women of childbearing potential must have a negative pregnancy test prior to receiving sunitinib malate. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of lutetium Lu 177 dotatate and sunitinib malate administration\n\nExclusion Criteria:\n\n* Patients who have not recovered from acute clinically significant adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia\n* Patients who are receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate or lutetium Lu 177 dotatate\n* Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin are excluded, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis. Note: Low molecular weight heparin is permitted provided the patient's INR is =\\\u003C 1.5 and is the preferred anticoagulant in this trial. Other non-coumarin-derivative anticoagulants including direct oral anticoagulants may be used with caution\n* Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain sunitinib tablets are excluded\n* Patients with any of the following conditions are excluded:\n\n  * Serious or non-healing wound, ulcer, or bone fracture\n  * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment\n  * Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry\n  * History of myocardial infarction, cardiac arrhythmia, stable\u002Funstable angina, symptomatic congestive heart failure, or coronary\u002Fperipheral artery bypass graft or stenting within 12 months prior to study entry\n  * History of pulmonary embolism within the past 12 months\n  * Class III or IV heart failure as defined by the New York Heart Association Class (NYHA) functional classification system\n* Patients receiving any medications or substances that are strong CYP3A4 inhibitors within 7 days before dosing, or strong CYP3A4 inducers within 12 days before dosing, are ineligible as sunitinib is a major substrate of CYP3A4. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\n* Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible\n* Patients with uncontrolled intercurrent illness\n* Pregnant women are excluded from this study because sunitinib malate is an anti-angiogenic agent and lutetium Lu 177 dotatate is a peptide receptor radionuclide therapy with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sunitinib malate and lutetium Lu 177 dotatate, breastfeeding should be discontinued if the mother is treated with sunitinib malate and lutetium Lu 177 dotatate. Breastfeeding should be discontinued for 2.5 months following the last lutetium Lu 177 dotatate treatment. These potential risks may also apply to other agents used in this study\n* Patients who have had prior treatment with sunitinib malate or lutetium Lu 177 dotatate therapy or other radiopharmaceuticals (including, but not limited to, metaiodobenzylguanidine \\[MIBG\\], yttrium-90 \\[Y-90\\], radioactive iodide \\[RAI\\]), as MIBG and RAI could potentially increase risk of myelodysplastic syndrome or irreversible hematologic toxicities",{"count":201,"type":20},24,[23],"This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone.",[205,31,206,207,208],"Metastatic Pancreatic Neuroendocrine Tumor","Stage III Pancreatic Neuroendocrine Tumor AJCC v8","Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","Unresectable Pancreatic Neuroendocrine Tumor","2026-05-12",{"date":211,"type":52},"2026-05-13",{"date":213,"type":52},"2024-08-14",{"date":215,"type":20},"2026-12-14",{"name":217,"class":218},"National Cancer Institute (NCI)","NIH",10,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100472167","incremental-value-of-magnetic-resonance-imaging-in-selection-of-pancreatic-cancer-patients-for-surgery-100472167","NCT05428358","Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery","Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.","MAGIPAC","Inclusion criteria:\n\n* Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board\n* No liver metastases on CT\n* At least 18 years old and able to provide informed consent\n* Expected pancreatic ductal adenocarcinoma based on CT scan\n\nExclusion criteria:\n\n* Metastatic disease\n* Prior receipt of neoadjuvant chemotherapy or downstaging\u002F-sizing treatment\n* Comorbidity rendering major surgery unfeasible (inoperable)\n* No informed consent\n* Unable to undergo MRI (Kidney insufficiency (eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)\n* Postoperative histology other than adenocarcinoma of pancreato-biliary origin.\n* MRI with liver-specific contrast performed during standard workup.","99 Years",{"count":230,"type":20},200,[150],"The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.",[179,31,234],"Liver Metastases",[236],"magnetic resonance imaging","2026-04-28",{"date":239,"type":52},"2026-04-29",{"date":241,"type":52},"2022-08-30",{"date":243,"type":20},"2028-12-01",{"name":245,"class":164},"University of Aarhus",3,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":270},"100578141","phase-3-lanreotide-versus-placebo-before-surgery-to-prevent-a-surgical-complication-called-a-pancreatic-fistula-100578141","NCT06807437","Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula","Inclusion Criteria:\n\n* Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential\n* Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration\u002Frandomization date\n* Participants must not have a known history of a prior diagnosis of malabsorption syndrome\n* Participants must not have been treated with any somatostatin analogue within 180 days prior to registration\u002Frandomization\n* Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration\u002Frandomization\n* Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration\u002Frandomization\n* Participants must be ≥ 18 years old\n* Participants must have a complete documented medical history and physical exam within 28 days prior to registration\u002Frandomization\n* Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL\u002Fmin using the following Cockcroft -Gault formula within 60 days prior to registration\u002Frandomization\n* Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:\n\n  * Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed\n  * Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels\n  * Bromocriptine: Dose adjustments may be considered to account for absorption changes\n  * Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary\n  * CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure\n* In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy\n\n  * NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible\n* In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation\n* Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase \\[AST\\] \\> 190 U\u002FL or alanine aminotransferase \\[ALT\\] \\> 320 U\u002FL) within 60 days prior to registration\u002Frandomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable\n* Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)\n* Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen\n* Participants must be offered the opportunity to participate in specimen banking\n* Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study\n* NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines\n* For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations",{"count":255,"type":20},274,[257],"PHASE3","This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.",[260,31],"Pancreatic Carcinoma","2026-03-25",{"date":263,"type":52},"2026-03-31",{"date":265,"type":52},"2025-05-09",{"date":267,"type":20},"2027-11-01",{"name":269,"class":82},"SWOG Cancer Research Network",118,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":165},"100513170","evaluation-of-endoscopic-ultrasound-guided-radiofrequency-ablation-for-the-management-of-pancreatic-tumors-erase-study-100513170","NCT05961982","Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study","Endoscopic Ultrasound-Guided Radiofrequency Ablation of Pancreatic Cysts - A Safety and Efficacy Trial (ERASE Study)","ERASE","Inclusion Criteria:\n\n* Age \\> 18 years\n* A diagnosis of a PCN confirmed by EUS-FNA including cyst fluid next generation sequencing (NGS) and\u002For EUS-guided needle-based confocal laser endomicroscopy (nCLE) and\u002For EUS- guided through-the-needle biopsy (TTNB)\n* The pancreatic cystic lesion (PCL) measures at least 2 cm in diameter on either CT or MRI\u002FMRCP or EUS and demonstrates concerning worrisome and\u002For high-risk features as defined by International Consensus Guidelines (2017 revised Fukuoka Guidelines)\n* The patient is not a surgical candidate. Common clinical scenarios include -\n\n  * Cirrhosis of the liver (common clinical scenario)\n  * Advanced ( \\>= 75 years) age (common clinical scenario)\n  * Morbid obesity\n  * Significant cardiorespiratory comorbidity\n  * Patient's choice (patient elects for non-surgical management)\n  * Other significant comorbid conditions that impose prohibitive surgical risks\n* Estimated life expectancy of at least 1 year\n* Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them\n* Women of childbearing potential must have a negative pregnancy test (serum\u002Furine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy\n* The patient prefers non-surgical management after consultation with hepato-pancreato-biliary (HPB) surgery\n* The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-guided injection of chemotherapy (Ohio State University \\[OSU\\] Institutional Review Board \\[IRB\\] protocol 2020C0198)\n\nExclusion Criteria:\n\n* A diagnosis of a benign or non-neoplastic PCL such as a pseudocyst confirmed by EUS-FNA including cyst fluid NGS and\u002For EUS-nCLE and\u002For EUS-TTNB\n* A diagnosis of a malignant PCN confirmed by evidence of adenocarcinoma and\u002For invasive carcinoma and\u002For distant metastases\n* Cysts or neuroendocrine tumors (NETS) involving or in close proximity to blood vessels, the biliary tree, or the main pancreatic duct where the zone of ablation is likely to compromise these structures\n* Acute pancreatitis in the preceding 4 weeks prior to date of EUS-RFA\n* Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it unsafe for the patient to participate in the study\n* Any psychiatric disorder making reliable informed consent impossible\n* Pregnancy or breast-feeding\n* Eastern Cooperative Oncology Group (ECOG) performance status 4\n* Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC)\n* Cardiac implantable electrical devices",{"count":280,"type":20},84,[150],"This clinical trial evaluates the safety and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for the management of patients with pancreatic tumors (including cysts) performed during recommended surveillance endoscopic ultrasound examinations. Pancreatic tumors (cysts) can progress to pancreatic cancer at rate of more than 25% per year risk. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage, and the five-year survival rate is currently less than 10%. It is projected to be the second leading cause of cancer-related mortality by the year 2030. A procedure known as radiofrequency ablation may help. Radiofrequency ablation is an established way to treat benign and cancerous tumors in the human body. In the last 5 years, radiofrequency ablation has been applied to treat precancerous tumors (including cysts) in the pancreas. This procedure implements a medical technology that destroys tumors in a much less invasive way compared to traditional surgical removal. By delivering a high-frequency alternating current, radiofrequency ablation uses electrical energy and heat to destroy cancer cells. Radiofrequency ablation is being recognized as a management option in patients with high-risk pancreatic tumors (cysts) but are not deemed surgical candidates. While surgical removal offers a chance of cure, pancreatic surgeries have 20-40% morbidity rate (short and long-term complication) and a 1-2% mortality rate in patients who are surgical candidates. Furthermore, radiofrequency ablation can potentially decrease the need for frequent imaging\u002Fsurveillance of the pancreatic tumor (cyst). In patients with immediate prohibitive, but reversible risks for surgery, radiofrequency ablation of a high-risk tumors (cysts) can potentially prevent further progression of the lesion and bridge the time before the need for surgical resection.",[31],"2026-03-20",{"date":286,"type":52},"2026-03-23",{"date":288,"type":52},"2023-04-24",{"date":290,"type":20},"2028-12-31",{"name":163,"class":164},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":172,"sex":16,"minAge":17,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":165},"100556541","mre-for-diagnosis-of-pancreatic-masses-100556541","NCT06526442","MRE for Diagnosis of Pancreatic Masses","Experimental and Clinical Study of Three-dimensional Magnetic Resonance Elastography to Evaluate Pancreatic Cancer and Interstitial Fibrosis","MREDPCM","Inclusion Criteria:\n\n1. granting of written informed consent\n2. age ≥18 years\n3. no history of extrapancreatic malignancy\n4. no preoperative biliary drainage\n5. definitive histologic evidence of PDAC in excisional biopsy\n6. with no less than three months of postoperative mortality or six months of follow- up\n\nExclusion Criteria:\n\n1. inability to re-review of tissue specimens\n2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection\n3. tumor diameters \\\u003C1.0 cm\n4. withdrawal\u002Fdropout during follow-up","80 Years",{"count":230,"type":20},"Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. The extracellular matrix (ECM) surrounding PDAC often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of PDAC. High order three-dimensional MR elastography (3D-MRE) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. However, there are no reports about the application of MRE imaging biomarkers to predict the prognosis of PDAC at home and abroad.",[31,304],"Magnetic Resonance Imaging",[306,307],"Pancreatic Cancer, solid pancreatic mass","Magnetic Resonance Elastography","2026-02-12",{"date":310,"type":52},"2026-02-13",{"date":312,"type":52},"2020-10-09",{"date":314,"type":20},"2027-06-01",{"name":316,"class":164},"Yu Shi",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":324,"maxAge":68,"enrollmentInfo":325,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":165},"100623440","endocrine-exocrine-functions-and-prognosis-after-pancreatectomy-100623440","NCT07396662","Endocrine-exocrine Functions and Prognosis After Pancreatectomy","The Analysis of Endocrine-exocrine Functions and Prognosis After Pancreatectomy","Inclusion Criteria:\n\n* All patients scheduled for pancreatectomy\n\nExclusion Criteria:\n\n* Age under 20 years or older than 75 years; Pregnancy","20 Years",{"count":326,"type":20},3500,"Pancreatic diseases often require surgery or invasive procedures to provide a chance for a cure. However, due to the pancreas's unique anatomical structure, its relative position to adjacent organs, and its dual endocrine and exocrine functions, the complexity of surgery is increased, impacting the patient's postoperative quality of life. Therefore, this project aims to retrospectively collect basic data, preoperative and postoperative blood tests (blood cell counts, biochemistry, tumor markers, glucose-related, lipid-related), and preoperative and postoperative imaging examinations (CT, MRI, Ultrasound, PET scan, Endoscopy, etc.) of patients who underwent pancreatic surgery at our hospital. We aim to compare whether surgical methods, lesion margin clearance rates, and postoperative remnant pancreatic volume affect the patient's endocrine function, exocrine function, quality of life, and disease prognosis. This analysis is intended to understand the indications, surgery-related factors, and prognosis for patients planning to undergo pancreatic surgery, with the expectation of providing more diverse and specific treatment recommendations for patients with pancreatic diseases in the future",[31],"2026-02-05",{"date":331,"type":52},"2026-02-09",{"date":333,"type":52},"2016-01-01",{"date":335,"type":20},"2034-12-31",{"name":337,"class":164},"National Taiwan University Hospital",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":165},"100547732","phase-2-rectus-sheath-block-with-liposomal-bupivacaine-versus-thoracic-epidural-analgesia-for-pain-control-following-pancreatoduodenectomy-100547732","NCT06411795","Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial","Inclusion Criteria:\n\n* Adult patients, age 18 and older, undergoing open pancreaticoduodenectomy at the University of Minnesota will be included in the study\n\nExclusion Criteria:\n\n* Patients with contraindication to block placement (coagulopathy, local anesthetic allergy, infection)\n* Patients with chronic opioid use (at least 30 milligram morphine equivalents \\[MME\\] for 3 or more weeks leading up to surgery)\n* Patients unable to understand the quality of recovery survey intellectual barriers. This will be determined by the primary investigator\u002Fattending anesthesiologist's discretion\n* Patient refusal and those who have opted out of research\n* Pregnant patients - will be assessed through review of the medical record",{"count":346,"type":20},78,[95],"This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.",[350,31],"Duodenal Neoplasm","2026-02-02",{"date":353,"type":52},"2026-02-03",{"date":355,"type":52},"2023-11-10",{"date":357,"type":20},"2028-01-01",{"name":359,"class":164},"Masonic Cancer Center, University of Minnesota",{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":16,"minAge":324,"maxAge":68,"enrollmentInfo":367,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":376,"locationsCount":165},"100622374","delayed-gastric-emptying-after-pancreatic-surgery-100622374","NCT07382791","Delayed Gastric Emptying After Pancreatic Surgery","The Analysis of Delayed Gastric Emptying After Pancreatic Surgery","Inclusion Criteria:\n\n1. Males or females aged 20 years or older.\n2. Patients scheduled to undergo pancreatic surgery.\n\nExclusion Criteria:\n\n1. Patients under 20 years of age at this hospital.\n2. Presence of other active malignancies prior to diagnosis.\n3. Minors, pregnant women, breastfeeding women, and patients with psychiatric disorders.",{"count":326,"type":20},"Delayed gastric emptying (DGE) is a common complication of pancreatic surgery. Once it occurs, it often affects the patient's postoperative quality of life and may even delay subsequent necessary treatments, such as adjuvant chemotherapy. Therefore, this project aims to retrospectively collect basic data, preoperative and postoperative blood tests (blood cell counts, biochemistry, tumor markers, glucose-related, lipid-related), and preoperative and postoperative imaging examinations (CT, MRI, Ultrasound, PET scan, Endoscopy, etc.) of patients who underwent pancreatic surgery at our hospital. We aim to compare whether surgical methods, the placement of gastrointestinal feeding tubes, lesion margin clearance rates, and postoperative remnant pancreatic volume affect the occurrence of delayed gastric emptying and related quality of life. This analysis is intended to understand and analyze the risk factors for delayed gastric emptying in pancreatic surgery patients, the indications for gastrointestinal feeding tube placement, as well as the management and prognosis of delayed gastric emptying, with the expectation of providing more diverse and specific treatment recommendations for patients with delayed gastric emptying after pancreatic surgery in the future.\n\nKeywords: Pancreatic surgery, Delayed gastric emptying, Gastrointestinal feeding tube III. Background Delayed Gastric Emptying after Pancreatic Surgery Delayed gastric emptying is a common complication of pancreatic surgery. However, once it occurs, it often affects the patient's postoperative quality of life and may even delay subsequent necessary treatments, such as adjuvant chemotherapy.\n\nIV. Objectives To compare whether surgical methods, the placement of gastrointestinal feeding tubes, lesion margin clearance rates, and postoperative remnant pancreatic volume affect the occurrence of delayed gastric emptying and related quality of life in patients.\n\nV. Methodology and Procedures Data Collection The Principal Investigator and Co-Investigator will retrospectively collect basic data of patients who underwent pancreatic surgery at this hospital. This includes preoperative and postoperative blood tests (blood counts, biochemistry, tumor markers, glucose-related, lipid-related) and imaging examinations (CT, MRI, Ultrasound, PET scan, Endoscopy, etc.). This data will be used to compare the impact of surgical methods, gastrointestinal feeding tube placement, margin clearance, and remnant pancreatic volume on the occurrence of delayed gastric emptying and related quality of life. The goal is to understand and analyze risk factors, indications for feeding tube placement, management, and prognosis.\n\nFrom the hospital portal system, approximately 500 medical records of patients with pancreatic diseases who underwent pancreatic surgery or invasive treatment performed by the Principal Investigator and Co-Investigator between January 2005 and July 2021 will be collected. This observational study will collect routine imaging and laboratory tests performed at the hospital to analyze treatment indications, surgical indicators, and prognosis.\n\nInclusion Criteria:\n\n1. Males or females aged 20 years or older.\n2. Patients scheduled to undergo pancreatic surgery.\n\nExclusion Criteria:\n\n1. Patients under 20 years of age at this hospital.\n2. Presence of other active malignancies prior to diagnosis.\n3. Minors, pregnant women, breastfeeding women, and patients with psychiatric disorders.\n\nStatistical Analysis Patient medical records will be utilized to analyze risk factors for delayed gastric emptying, indications for gastrointestinal feeding tube placement, management, and prognosis for patients undergoing pancreatic surgery, aiming to provide diverse and specific treatment recommendations in the future.\n\nConfidentiality and Privacy Protection To ensure patient privacy and personal information security, after querying the relevant data of enrolled subjects, the data sheet will use new codes to represent the subjects' identities. Experimenters and analysts will only have access to this de-linked data sheet for analysis. All electronic data will be password-protected and accessible only by specific personnel related to this project.\n\nAll data not used or after analysis will be stored at the NTU Department of Surgery for 15 years and then destroyed by shredder or incineration to remove identifiable personal data, unless required for medical or research purposes. Researchers (including external personnel) will sign a written pledge stating that medical record data will not be reused, disclosed to third parties, or used for purposes outside this study, unless required by law or audited by the Research Ethics Committee.\n\nBudget and Equipment Item Purpose Amount (TWD) Database Analysis Software Data Analysis 50,000 Statistical Consulting Data Analysis 50,000 Statistical Consulting Chart Creation 50,000 English Editing, Publication, Printing, Stationery Thesis Publication 50,000 Part-time Student",[31],[371],"Pancreatic surgery, Delayed gastric emptying, Gastrointestinal feeding tube","2026-01-27",{"date":353,"type":52},{"date":333,"type":52},{"date":335,"type":20},{"name":337,"class":164},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":324,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":21,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":165},"100612741","phase-2-carbon-ion-radiotherapy-in-frail-patients-with-pancreatic-cancer-100612741","NCT07257523","Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer","Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer: A Prospective Phase II Study","Inclusion Criteria:\n\n\\- Histologically confirmed pancreatic cancer without distant metastasis.\n\nNot eligible for surgery or systemic chemotherapy, defined as:\n\nClinical Frailty Scale (CFS) score ≥ 4, or Significant medical comorbidities precluding standard treatment. Patients who decline surgery and chemotherapy after adequate counseling. Age ≥ 19 years. Able to provide written informed consent. Eligible and willing to receive carbon ion radiotherapy.\n\nExclusion Criteria:\n\n* Age \\\u003C 19 years. Presence of distant metastasis at baseline imaging (CT\u002FMRI\u002FPET-CT). Active or uncontrolled infection that may interfere with treatment. Active bleeding or bleeding tendency requiring immediate medical intervention. Pregnant or breastfeeding women. Any condition that, in the investigator's judgment, makes participation unsafe or inappropriate (e.g., severe organ dysfunction preventing radiotherapy).\n\nInability to comply with study procedures or follow-up schedule.",{"count":385,"type":20},33,[95],"\"This prospective, single-arm phase II study aims to evaluate the efficacy and safety of carbon ion radiotherapy in frail patients with histologically confirmed, non-metastatic pancreatic cancer who are not eligible for surgery or systemic chemotherapy. Frail status is defined as a Clinical Frailty Scale (CFS) score ≥4 or the presence of significant medical comorbidities limiting aggressive treatment.\n\nCarbon ion radiotherapy, known for its superior dose distribution and high linear energy transfer, may offer improved tumor control with acceptable toxicity in this vulnerable population. This study will assess overall survival, progression-free survival, local control, toxicity, and quality of life.",[31],"2025-11-30",{"date":391,"type":52},"2025-12-02",{"date":393,"type":52},"2025-09-23",{"date":395,"type":20},"2029-07",{"name":397,"class":164},"Yonsei University",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":16,"minAge":406,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":409,"briefSummary":410,"conditions":411,"keywords":420,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":443},"100499704","phase-2-determine-trial-treatment-arm-04-trastuzumab-in-combination-with-pertuzumab-in-adult-paediatric-and-teenageyoung-adult-patients-with-cancers-with-her2-amplification-or-activating-mutations-100499704","NCT05786716","DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 04 (TRASTUZUMAB AND PERTUZUMAB) OUTLINED BELOW\\*\n\n\\*When trastuzumab- and pertuzumab-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the trastuzumab- and pertuzumab-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring HER2 amplification, or an appropriate activating mutation as defined by the MTB, using an analytically validated next-generation sequencing method.\n\n• A HER2 amplification copy number between 5-9 will require an MTB discussion. A HER2 amplification copy number ≥10 will be fast-tracked for an MTB recommendation, unless there are any patient-specific individualities (such as multiple gene amplifications) that require MTB discussion.\n\nB. Age 12 years or above.\n\nC. Women of childbearing potential are eligible provided that they meet the following criteria:\n\nHave a negative serum or urine pregnancy test before enrolment and;\n\nAgree to use one form of effective birth control method such as:\n\nI. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal):\n\nII. progestogen-only hormonal contraception associated with or without inhibition of ovulation (oral, injectable or implantable)\n\nIII. intrauterine device (IUD)\n\nIV. intrauterine hormone-releasing system (IUS)\n\nV. bilateral tubal occlusion\n\nVI. vasectomised partner\n\nVII. sexual abstinence\n\nVIII. male or female condom with or without spermicide\n\nIX. cap, diaphragm or sponge with spermicide\n\nEffective from the first administration of trastuzumab or pertuzumab (whichever is first), throughout the trial and for seven months after the last administration of trastuzumab or pertuzumab (whichever is later).\n\nD. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of trastuzumab or pertuzumab (whichever is first), throughout the trial and for seven months after the last administration of trastuzumab or pertuzumab (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses an effective method of contraception as in C, above.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nE. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nF. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nG. PAEDIATRIC PATIENTS (\\\u003C18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nExclusion Criteria:\n\nA. Diagnosis of HER2-positive early or metastatic breast cancer.\n\nB. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or within seven months following their last dose of trastuzumab or pertuzumab (whichever is later).\n\nC. Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.\n\nD. Known hypersensitivity to trastuzumab or pertuzumab, murine proteins, or to any of the excipients.\n\nE. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during trastuzumab and pertuzumab treatment or within six months after the final dose of trastuzumab and pertuzumab.\n\nF. Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias (within three months), NYHA class III or IV congestive heart failure.\n\nLeft Ventricular Ejection Fraction \\\u003C55%.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]) or cardiovascular event (including acute myocardial infarction \\[MI\\]) within three months before the first dose of trastuzumab and pertuzumab.\n\n• Patients with primary CNS tumours may be considered unless intra-tumoural bleeding has occurred within 2 weeks of the first dose of trastuzumab and pertuzumab, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nG. Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to trastuzumab or pertuzumab.\n\nH. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.\n\nI. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of trastuzumab and pertuzumab, including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided the each of the following conditions are met:\n\n* CD4 count ≥350\u002FμL;\n* undetectable viral load;\n* receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* no HIV\u002F acquired immune deficiency syndrome (AIDS)-associated opportunistic infection in the last 12 months.","12 Years",{"count":408,"type":20},30,[95,257],"This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.\n\nTrastuzumab and pertuzumab work in patients with these types of cancers which have a molecular alteration called HER2 amplification or HER2 activating mutation.\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which are also HER2 amplified or HER2 mutated. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[412,32,413,414,415,416,31,26,417,418,419],"Haematological Malignancy","Urinary Bladder Neoplasm","Gallbladder Neoplasms","Salivary Gland Neoplasm","Lung Neoplasm","Prostatic Neoplasm","Skin Neoplasm","Solid Tumour",[421,422,108,423,424,425,426,427,428,429,430,431,432,433,434],"Adult","Antibodies, monoclonal","Child","Molecular Targeted Therapy","Mutation","Paediatric","Pertuzumab","Precision Medicine","Rare","Receptor, ErbB-2","Targeted","Trastuzumab","Tumour-agnostic","Young adult","2025-11-25",{"date":391,"type":52},{"date":438,"type":52},"2023-03-07",{"date":440,"type":20},"2029-10",{"name":442,"class":164},"Cancer Research UK",27,{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":165},"100596447","mscan-ctdna-methylation-as-prognostic-and-theranostic-tool-for-pancreatic-cancer-100596447","NCT07045571","MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer","Methylation Signature of Circulating Tumour DNA as a Prognostic and Theranostic Tool for Managing Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nPatients meeting all inclusion criteria are eligible to enter this study, including but not limited to:\n\n1. Age range between 18 and 80 years old;\n2. Identification of pancreatic space-occupying lesions through imaging examinations, with a high suspicion of pancreatic malignant tumors and planned for surgical treatment or tissue biopsy for pathological confirmation;\n3. According to RECIST 1.1 evaluation criteria, having at least one measurable lesion (the longest diameter of the target lesion on spiral CT scan ≥10mm);\n4. Ability to provide tumor tissue and blood samples;\n5. Stable vital signs, ECOG score of 0-1;\n6. Liver function with AST and ALT ≤ 5 times the upper limit of normal (ULN), Child-Pugh classification of A or B; white blood cell count \\> 3×10\\^9\u002FL, absolute neutrophil count ≥ 1.5×10\\^9\u002FL; platelets ≥ 75×10\\^9\u002FL; hemoglobin ≥ 90g\u002FL; creatinine clearance rate ≥ 60ml\u002Fmin; total bilirubin ≤ 3 times ULN;\n7. Reproductive-age patients and their spouses willing to adopt contraceptive measures; female patients must undergo a pregnancy test (serum or urine) within 7 days before enrollment with a negative result.\n8. Voluntarily participate in this experimental project, patients with good compliance; if the subject is unable to read or sign, the informed consent form must be signed by a legal representative with the subject's informed consent, and for subjects incapable of expressing consent, the introduction and explanation shall be provided to their legal representative, who will then sign the informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any of the exclusion criteria will not be eligible for inclusion, including but not limited to:\n\n1. Unable to provide tumor tissue and blood samples;\n2. Previously received molecular targeted therapy, immunotherapy, or anti-tumor radiochemotherapy before this study;\n3. History of malignancies other than pancreatic malignancy;\n4. Presence of other severe diseases, including but not limited to uncontrolled congestive heart failure (NYHA class III or IV), unstable angina, poorly controlled arrhythmias, uncontrolled moderate to severe hypertension (SBP \\> 160mmHg or DBP \\> 100mmHg);\n5. Uncontrolled diabetes;\n6. Active infection;\n7. Patients with active autoimmune diseases requiring long-term use of steroids;\n8. Patients who have undergone allogeneic transplantation;\n9. Active psychiatric disorders affecting informed consent and\u002For protocol compliance;\n10. Other severe illnesses deemed inappropriate for participation in this study by investigators.",{"count":452,"type":20},1000,"Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.",[31,103],[456,457,458,459,460,461],"Pancreatic ductal adenocarcinoma","Liquid biopsy","CtDNA","DNA methylation","Early diagnosis","Prognosis","2025-06-29",{"date":464,"type":52},"2025-07-01",{"date":466,"type":52},"2022-10-30",{"date":468,"type":20},"2026-07-22",{"name":470,"class":164},"Yingbin Liu, MD, PhD, FACS",{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":479,"enrollmentInfo":480,"targetDuration":482,"studyType":71,"phases":4,"briefSummary":483,"conditions":484,"keywords":492,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":516},"100400392","osprey-is-a-post-market-global-multicentre-observational-prospective-registry-100400392","NCT04493632","OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.","OncoSil Pancreatic Cancer Post-marketing Clinical REgistrY (OSPREY)","OSPREY","Inclusion Criteria:\n\n1. Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC).\n2. Patients who undergo OncoSil™ implantation at an eligible treatment facility.\n3. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPREY Patient Registry.\n4. Pancreatic target tumour recommended size of \\\u003C7 cm (longest diameter) and \\\u003C110 cc volume.\n5. A clinically acceptable ECOG performance status.\n6. Patients ≥ 18 years of age at screening.\n7. To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to the approved prescribing schedule) post Registry enrolment.\n8. Adequate biochemical tests, coagulation profile, haematological, renal, and hepatic function as determined by the Treating Physician.\n\nExclusion Criteria:\n\n1. Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREY Patient Registry.\n2. Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored).\n3. Evidence of distant metastases based on review of baseline CT scan.\n4. More than one primary lesion.\n5. In the opinion of the Treating Physician, EUS-directed implantation posing undue patient risk. This includes:\n\n   * where previous EUS-FNA was considered technically too difficult to perform;\n   * imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;\n   * presence (or significant risk) of varices near to the target tumour.\n6. Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).\n7. In the setting of recent, clinically significant pancreatitis, implantation is not recommended.\n8. Pregnant or intending to commence a pregnancy within 12-months of the intended date of implantation or breastfeeding.\n9. Patients who have a known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components","90 Years",{"count":481,"type":20},500,"24 Months","The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.\n\nThe Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.",[31,485,486,487,488,489,490,491],"Digestive System Neoplasm","Neoplasms by Site","Neoplasms","Endocrine Gland Neoplasm","Digestive System Disease","Pancreatic Diseases","Endocrine System Diseases",[179,493,494,495,496,497,498,499,500,501,502,503,504,505,506],"Pancreas","Metastases","Pancreatic tumor","Unresectable","Locally advanced","Implantable","Radiographic","Device","Phosphorous-32","OncoSil™","Brachytherapy","Gemcitabine","Nab-paclitaxel","Abraxane","2024-04-29",{"date":509,"type":52},"2024-04-30",{"date":511,"type":52},"2022-04-12",{"date":513,"type":20},"2027-10-01",{"name":515,"class":59},"OncoSil Medical Limited",9,{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":21,"phases":527,"briefSummary":528,"conditions":529,"keywords":532,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":219},"100445654","phase-2-preoperative-mfolfirinox-or-gem-nab-p---isotoxic-high-dose-sbrt-for-borderline-resectable-pancreatic-adenocarcinoma-100445654","NCT05083247","Preoperative mFOLFIRINOX (or Gem-Nab-P) +\u002F- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","Preoperative Treatment With mFOLFIRINOX (or Gem-Nab-P) +\u002F- Isotoxic High-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for Borderline Resectable Pancreatic Adenocarcinoma: a Randomised Phase II Study (STEREOPAC)","STEREOPAC","Inclusion criteria:\n\n* Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinated process or body or tail. Diagnosis should be verified by local pathologist\n* cTNM stage: T1-4N0-2M0\n* Confirmation of clinical and radiographic stage as borderline resectable (CT scan and\u002For MRI scan with contrast according to the NCCN criteria) by a multidisciplinary board, composed by a dedicated oncological surgeon, radiologist and GI oncologist)\n* Age \\> 18 years old\n* No prior chemotherapy or radiation for pancreatic cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* No grade ≥ 2 neuropathy\n* Laboratory parameters as follows:\n* Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³\n* Platelet count ≥ 100,000\u002Fmm³\n* Hemoglobin ≥ 9 g\u002FdL\n* Creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated GFR \\>45 mL\u002Fmin\n* Bilirubin ≤ 1.5 x ULN, including after adequate biliary stenting with metal stent (ideally 4 cm length)\n* Aspartate aminotransferase (AST) \u002F alanine aminotransferase (ALT) ≤ 2.5x ULN\n* CA 19.9 \\\u003C 2500 kU\u002Fl (baseline, prior to any therapy and absence of cholestasis)\n\nExclusion Criteria:\n\n* Evidence of extrapancreatic disease on diagnostic imaging (CT, MRI or PET scan), histologically proven or at laparoscopy, including distal nodal involvement beyond the peripancreatic tissues (including non-regional lymph node involvement, ie: proven involvement of precaval lumbar lymphadenopathy(ies) and\u002For distant metastases\n* Locally advanced disease as defined by the NCCN criteria (version 2.2021) ie \\> 180° arterial encasement (SMA and CA) unreconstructible venous encasement (SMV\u002FPV) due to tumor involvement or occlusion of a long segment.\n* CA 19.9 \\> 2500 kU\u002Fl (baseline and absence of cholestasis)\n* Contraindication of surgery (general)\n* Contraindications to receive FFX or gemcitabine-nab-Paclitaxel\n* History of radiotherapy of the upper abdomen\n* Prior treatment with oxaliplatin, irinotecan, fluoruouracil or capecitabin\n* Patient \\\u003C 18 years old\n* Major surgery within 4 weeks of study entry\n* Uncontrolled pre-existing disease including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina, social \u002F psychiatric disorder that would limit compliance to treatment and good understanding of the informed consent form\n* Other concurrent anticancer therapies\n* Existence of another active neoplasia other than basal cell carcinoma of the skin, cervical carcinoma in situ or non-metastatic prostate cancer. Patients who have a history of neoplasia must have been in remission for more than 5 years to be included in the protocol\n* Pregnant or breastfeeding women; for women of childbearing potential only, a negative pregnancy test done \\\u003C 7 days prior to registration is required. Using of reliable contraception for at least 1 month before treatment is mandatory\n* Chronic concomitant treatment with strong inhibitors of cytochrome p450, family 3, subfamily a, polypeptide 4 gene (CYP3A4) is not allowed on this study; patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study\n\nAdditional exclusion criteria before randomisation:\n\n* Progressive disease (RECIST or PETCT, including non locoregional nodal involvement and increase of CA 19.9 by 20%) after receiving 4 cycles of FFX (or G\u002FNP), including shift chemotherapy in case of early progression.\n* CA 19.9 \\> 1000 kU\u002Fl after neoadjuvant therapy.\n* Presence of unmanageable toxicity during the first part of neoadjuvant chemotherapy (first 4 cycles or 6 doses of FFX or G\u002FNP, respectively.\n* Pancreatic tumour \\> 7.0 cm in greatest axial dimension at the time of randomization\n* Massive invasion of the stomach or intestines and\u002For direct intestinal invasion of the mucosae visible at ultrasoundendoscopy\n* Active gastric or duodenal ulcer disease at the time of randomization. Tolerated in case of antecedent without active ulcer (confirmation by endoscopy before iHD-SBRT)",{"count":526,"type":20},256,[95],"Surgical resection is the only potentially curative treatment for patients with pancreatic cancer with the aim of curative R0 resection and related improvement of survival. As a standard, surgery is usually followed by adjuvant therapy that improves survival but neoadjuvant therapy (NAT) is a rapidly emerging concept that needs to be explored and validated in terms of therapeutic options in borderline resectable pancreatic tumors. In this setting, preoperative FFX seems to be feasible and can be prolonged by radiation therapy. However, the exact and best therapeutic sequence is not yet known and the additional role of adding isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT) to chemotherapy requires validation in randomised trials. We propose to evaluate the impact and efficacy of adding iHD-SBRT to preoperative neoadjuvant mFFX or Gem-NabP in patients with borderline resectable pancreatic adenocarcinoma.",[31,530,531],"Pancreatic Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma",[533,534,535,536],"borderline resectable pancreatic cancer","neoadjuvant therapy","stereotactic body radiation therapy","chemotherapy","2023-05-22",{"date":539,"type":52},"2023-05-23",{"date":541,"type":52},"2023-03-24",{"date":543,"type":20},"2030-12-31",{"name":545,"class":164},"Erasme University Hospital"]